Washington University Launches $1.47M Trial to Test Whether Insomnia Drug Suvorexant Can Slow Alzheimer's Pathology
Key Insights
Washington University in St. Louis received a $1.47 million NIA R01 renewal to evaluate suvorexant's chronic effects on Alzheimer's biomarkers in a six-month, 200-participant randomized trial.
Prior research showed suvorexant acutely reduced the CSF phosphorylated tau (search)-181 to unphosphorylated tau-181 ratio, a key fluid biomarker of tau pathology.
The trial targets cognitively normal, amyloid-positive adults aged 65+ with insomnia, positioning suvorexant as a candidate for secondary prevention rather than symptom management.
A research team at Washington University in St. Louis has secured a $1.47 million National Institute on Aging R01 renewal grant to investigate whether chronic treatment with the FDA-approved insomnia medication suvorexant can reduce Alzheimer's disease (search) biomarker burden in older adults who already carry amyloid pathology. The six-month randomized, placebo-controlled trial positions the widely prescribed sleep aid as a potential secondary prevention strategy — a departure from its established use for symptom management in insomnia.
The study, led by principal investigator Dr. Brendan Lucey, a neurologist at the Washington University Center for Sleep Medicine, builds on prior findings from the same group that demonstrated suvorexant's acute effects on key Alzheimer's biomarkers. Earlier work showed that overnight sleep disruption increases cerebrospinal fluid (CSF) amyloid-β levels by approximately 30%, and preliminary data revealed that suvorexant acutely reduces the ratio of phosphorylated tau (search)-181 to unphosphorylated tau-181 (pT181/T181) in CSF — a fluid biomarker increasingly used to gauge tau pathology.
A Mechanistic Niche Distinct from Anti-Amyloid Therapies
Suvorexant belongs to a class of drugs known as dual orexin (search) receptor antagonists (DORAs). By blocking wake-promoting orexin neuropeptides, the drug consolidates sleep. The hypothesis under investigation is that sustained sleep improvement reduces the ongoing production and accumulation of pathological proteins such as amyloid-beta (search) and tau (search) — rather than clearing existing pathology, as anti-amyloid immunotherapies like lecanemab and donanemab aim to do.
"Whether that effect is sufficient, durable, or additive with clearance-based approaches remains an open question the trial is designed to begin answering," the research team noted.
Trial Design and Endpoints
The trial will enroll 200 cognitively normal, amyloid-positive adults aged 65 or older who have symptomatic insomnia. Using an adaptive design, the study aims to optimize parameters ahead of a larger prevention trial. Beyond the primary endpoint of CSF pT181/T181, the investigators will assess a broad pharmacodynamic dataset including plasma and CSF amyloid-β, multiple phosphorylated tau (search) species, markers of microglial function, synaptic integrity, and non-tau neurodegeneration.
The use of an existing, widely prescribed agent with an established safety profile allows the study to bypass early-phase tolerability hurdles that typically slow novel therapeutic development.
Caution Amid Promise
Despite the encouraging preliminary data, Dr. Lucey has urged restraint regarding off-label use of suvorexant for Alzheimer's prevention. "It would be premature for people worried about developing Alzheimer's to see this as a reason to start taking suvorexant every night," he said, while adding, "I hope that one day we'll develop medications that harness the connection between sleep and Alzheimer's to prevent cognitive decline. But we're not there yet."
The link between sleep disorders and Alzheimer's is well-documented: trouble sleeping is often among the earliest signs of the disease, appearing even before cognitive symptoms. During sleep, the brain activates its waste-clearance system, flushing out potentially harmful proteins. Disrupted sleep may impair this vital process, leaving amyloid-beta (search) and tau (search) to accumulate.
The study represents a clinically actionable exploration of whether pharmacologically improving sleep can measurably alter the trajectory of Alzheimer's pathology before cognitive decline emerges.